Cable Hill Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Cable Hill Partners’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,000	Closed	-$13K	–	442
2019 Q1	$13K	Buy	10,000 +5,000	+100%	+$6.22K	﹤0.01%	439
2018 Q4	$5K	Sell	5,000 -715	-13%	-$1.09K	﹤0.01%	569
2018 Q3	$11K	Hold	5,715	–	–	﹤0.01%	409
2018 Q2	$10K	Hold	5,715	–	–	﹤0.01%	473
2018 Q1	$12K	Buy	5,715 +4,572	+400%	+$10.7K	0.01%	439
2017 Q4	$3K	Sell	1,143 -2,286	-67%	-$4.99K	﹤0.01%	826
2017 Q3	$9K	Buy	3,429 +2,286	+200%	+$5.67K	﹤0.01%	604
2017 Q2	$3K	Buy	+1,143	New	+$3.19K	﹤0.01%	640

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cable Hill Partners's LCTX Position: Q2 2019 in Review

Cable Hill Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 10,000 shares — an estimated $13K sold.

Cable Hill Partners first reported a position in LCTX in Q2 2017 and held it in 8 quarters. The position peaked at $13K in Q1 2019. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

Cable Hill Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 10,000 Lineage Cell Therapeutics shares in Q2 2019, an estimated $13K.
Cable Hill Partners first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 8 quarters.
Cable Hill Partners's Lineage Cell Therapeutics position peaked at $13K in Q1 2019.
107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.